Vascular intervention technology provider BrosMed Medical took part in a series B-plus round for Brattea, a China-based developer of renal denervation (RDN) medical technology, on Tuesday sized at over $20m.
Healthcare-focused private equity fund Kuanping Capital led the round, which also featured Hengxu Capital, Pudong Science & Technology Investment, Northern Light Venture Capital, BioTrack Capital and Sherpa Healthcare Partners.
Brattea is the developer of a series of RDN products used in the treatment of hypertension, diabetes and cancer-related pain, including a basket-shaped six-electrode ablation catheter.
The company did not reveal details of its previous funding but identified Northern Light Venture Capital, Sherpa Healthcare Partners and BioTrack Capital as existing investors.
Image courtesy of Brattea.
